Coronavirus Update: How Should Remdesivir Be Priced? ICER Are In Two Minds
Plus Moderna and Daiichi Sankyo Updates
Executive Summary
Independent drug cost watchdog updates its twin pricing estimates for Gilead's drug - but dexamethasone could tip the balance again.
You may also be interested in...
Oncology Deal-Making The Daiichi Way
Daiichi Sankyo’s relatively young strategic pivot into oncology is paying major dividends, with two huge global deals with AstraZeneca now in the bag within 18 months. Scrip takes a closer look with the help of insights from the Japanese firm’s global oncology R&D head.
Moderna’s COVID-19 Vaccine Spurs Immune Response In All Phase I Subjects At All Doses
Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.
Gilead Sets Remdesivir Price, Commits Nearly All Near-Term Supplies To US
A five-day course will cost $2,340 for governments in developed countries and $3,120 for commercial payers. The US will get 100% of remdesivir manufactured by Gilead in July.